

TABLE OF CONTENTS

0. Executive Summary	21
1. Introduction to Cell Therapy	25
Introduction.....	25
Historical landmarks of cell therapy.....	25
Interrelationship of cell therapy technologies	27
Cells and organ transplantation	27
Cells and protein/gene therapy	28
Cell therapy and regenerative medicine.....	29
Cells therapy and tissue engineering	29
Therapy based on cells involved in disease	30
Advantages of therapeutic use of cells.....	30
Use of cells for improving drug delivery.....	31
2. Cell Therapy Technologies	33
Introduction.....	33
Cell types used for therapy	33
Sources of cells.....	33
Xenografts	34
Cell lines.....	34
<i>Immortalized cells.....</i>	<i>34</i>
Blood component therapy	34
<i>Therapeutic apheresis.....</i>	<i>34</i>
<i>Leukoreduction</i>	<i>35</i>
<i>Platelet therapy</i>	<i>35</i>
Basic technologies for cell therapy	36
Cell culture.....	36
<i>Observation of stem cell growth and viability.....</i>	<i>36</i>
<i>Companies involved in cell culture.....</i>	<i>37</i>
Cell sorting.....	38
<i>Flow cytometry.....</i>	<i>38</i>
<i>A dielectrophoretic system for cell separation</i>	<i>39</i>
<i>Molecular beacons for specific detection and isolation of stem cells.....</i>	<i>39</i>
<i>Multitarget magnetic activated cell sorter.....</i>	<i>40</i>
<i>Nanocytometry</i>	<i>40</i>
<i>Companies supplying cell sorters</i>	<i>40</i>
<i>Dynabead technology for cell sorting</i>	<i>41</i>
<i>ALDESORTER system for isolation of stem cells.....</i>	<i>41</i>
<i>Adult stem cell sorting by identification of surface markers.....</i>	<i>42</i>
Cell analysis	42
Preservation of cells	43
<i>Innovations in cryopreservation</i>	<i>43</i>
Packaging of cells.....	43
Selective expansion of T cells for immunotherapy	44
Cloning and cell therapy	44
Techniques for cell manipulation	45
Cell-based drug discovery.....	45
Cells as vehicles for drug delivery.....	48
RBCs as drug delivery vehicles	48
Drug delivery systems for cell therapy.....	48
Intravenous delivery of stem cells.....	48
Pharmacologically active microcarriers.....	49
Devices for delivery of cell therapy.....	49
Artificial cells	50
Applications of artificial cells.....	50
Cell encapsulation	51
Diffusion capsule for cells.....	51
Encapsulated cell biodelivery	52
Therapeutic applications of encapsulated cells	52
Nitric oxide delivery by encapsulated cells	53
Implantation of microencapsulated genetically modified cells	54
Ferrofluid microcapsules for tracking with MRI.....	54
Companies involved in encapsulated cell technology.....	55
Electroporation	55
Gene therapy	56
Cell-mediated gene therapy	56
<i>Fibroblasts</i>	<i>56</i>

Chondrocyte.....	57
Skeletal muscle cells	57
Vascular smooth muscle cells	58
Keratinocytes	58
Hepatocytes	59
Lymphocytes	59
Mammalian artificial chromosomes.....	59
In vivo tracking of cells	59
Molecular imaging for tracking cells.....	60
MRI technologies for tracking cells	60
Superparamagnetic iron oxide nanoparticles as MRI contrast agents	61
Visualization of gene expression in vivo by MRI.....	61
Role of nanobiotechnology in development of cell therapy	61
Cell transplantation for development of organs	62
Cells transplantation and tolerance	62
Strategies to improve tolerance of transplanted cells.....	63
Encapsulation to prevent immune rejection	63
Prevention of rejection of xenotransplants.....	63
Expansion of allospecific regulatory T cells	64
Removal and replacement of pathogenic cells of the body.....	64
Therapeutic leukocytapheresis	64
3. Stem Cells.....	66
Introduction.....	66
Biology of stem cells	67
Embryonic stem cells.....	67
Growth and differentiation of ESCs.....	67
Regulation of stem cell self-renewal and differentiation	68
Role of Pax3 in stem cell differentiation.....	68
ESCs and signaling pathways.....	69
Genetic signature of of stem cells.....	69
Epigenetics of hESCs	69
Chromatin as gene regulator for ESC development.....	70
Mechanism of differentiation of ESCs	70
Chemical regulation of stem cell differentiation	71
Comparison of development of human and mouse ESCs	71
In vitro differentiation of hESCs	71
Global transcription in pluripotent ESCs	72
Signaling pathways and transcription factors in ESCs.....	72
Stem cells in the pituitary gland.....	73
hESCs in stead of oocytes for reprogramming human somatic nuclei	73
Mechanism of regulation of stem cells for regeneration of body tissues	73
Role of microenvironments in the regulation of stem cells	73
Regulation and regeneration of intestinal stem cells	74
Parthenogenesis and human stem cells.....	74
Uniparental ESCs	75
Bone marrow stem cells.....	76
Hematopoietic stem cells	76
Role of HSCs in the immune system	78
Derivation of HSCs from ESCs.....	78
Mesenchymal stem cells.....	78
Multipotent adult progenitor cells	80
Side population (SP) stem cells.....	80
Differentiation of adult stem cells.....	80
Growth and differentiation of HSCs.....	81
Signaling pathways in the growth and differentiation of HSCs	81
Mathematical modeling of differentiation of HSCs.....	82
Role of prions in self renewal of HSCs	82
Sources of stem cells	83
Sources of of human embryonic stem cells	83
Nuclear transfer to obtain hESCs.....	83
Direct derivation of hESCs from embryos without nuclear transfer.....	84
Alternative methods of obtaining hESCs.....	85
Establishing hESC lines without destruction of embryo	85
Altered nuclear transfer	86
Small embryonic-like stem cells	86
Advantages and disadvantages of ESCs for transplantation	86
Use of ESC cultures as an alternative source of tissue for transplantation.....	87
Spermatogonial stem cells	88
Amniotic fluid as a source of stem cells	88
Generation of iPS cells from AF cells	89

Placenta as source of stem cells	89
<i>Amnion-derived multipotent progenitor cells</i>	89
<i>Placenta as a source of HSCs</i>	90
<i>Umbilical cord as a source of MSCs</i>	90
Umbilical cord blood as source of neonatal stem cells	91
<i>Cryopreservation of UCB stem cells</i>	92
<i>UCB as source of MSCs</i>	92
<i>Applications of UCB</i>	92
<i>Advantages of UCB</i>	93
<i>Limitations of the use of UCB</i>	93
<i>Licensing and patent disputes involving UCB</i>	94
<i>Infections following UCB transplants</i>	95
<i>Unanswered questions about UCB transplantation</i>	95
<i>Companies involved in UCB banking</i>	96
<i>UCB banking in the UK</i>	97
<i>US national UCB banking system</i>	97
<i>Future prospects of UCB as a source of stem cells</i>	98
Induced pluripotent stem cells derived from human somatic cells	99
Characteristics of iPSCs	99
DNA methylation patterns of iPS cells	100
iPSCs derived from blood	100
iPSCs derived from skin	100
Use of retroviral vectors for generation of iPSCs	100
Use of non-integrating viral vectors for generation of iPSCs.....	101
Clinical relevance of iPSCs.....	101
Sources of adult human stem cells	103
Adipose tissue as a source of stem cells.....	103
<i>Transforming adult adipose stem cells into other cells</i>	103
<i>iPSCs derived from adult human adipose stem cells</i>	104
Skin as a source of stem cells.....	104
<i>Controlling the maturation of embryonic skin stem cells</i>	104
<i>Epidermal neural crest stem cells</i>	105
<i>Follicle stem cells</i>	105
<i>Mesenchymal stem cells in skin</i>	105
<i>Regulation of stem cells in hair follicles</i>	106
<i>Skin-derived precursor cells</i>	106
Stem cells in teeth	106
Peripheral blood stem cells.....	107
Spleen as a source of adult stem cells	108
Search for master stem cells	108
Vascular cell platform to self-renew adult HSC.....	108
Adult stem cells vs embryonic stem cells	109
Transdifferentiation potential of adult stem cells	109
Neural crest stem cells from adult hair follicles	110
Stem cells obtained from blood in adults.....	111
VENT cells	111
Stem cell banking	112
Stem cell technologies	112
Analysis of stem cell growth and differentiation	112
Tracking self-renewal and expansion of transplanted muscle stem cells	112
Stem cell biomarkers.....	113
<i>Endoglin as a functional biomarker of HSCs</i>	113
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs</i>	113
<i>SSEA-4 as biomarker of MSCs</i>	114
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells</i>	114
<i>Neural stem cell biomarker</i>	114
<i>Protein expression profile as biomarker of stem cells</i>	114
<i>Real-time PCR for quantification of protein biomarkers</i>	115
Study of stem cell pathways.....	115
Study of stem cell genes.....	115
Gene inactivation to study hESCs.....	116
<i>RNAi to study gene inactivation in hESCs</i>	116
<i>Study of ESC development by inducible RNAi</i>	117
<i>Targeting Induced Local Lesions in Genomes</i>	117
<i>Homologous recombination of ESCs</i>	117
<i>Immortalization of hESCs by telomerase</i>	118
Gene modification in genomes of hESCs and hiPSCs using zinc-finger nuclease.....	118
miRNA and stem cells	119
<i>Role of miRNAs in gene regulation during stem cell differentiation</i>	119
<i>Influence of miRNA on stem cell formation and maintenance</i>	119
<i>Transcriptional regulators of ESCs control miRNA gene expression</i>	120

Stem cells and cloning	120
<i>Cell nuclear replacement and cloning</i>	120
<i>Nuclear transfer and ESCs</i>	121
<i>Cloning from differentiated cells</i>	122
<i>Cloning mice from adult stem cells</i>	122
<i>Creating interspecies stem cells</i>	123
<i>Cloned cells for transplantation medicine</i>	123
<i>Claims of cloning of hESCs</i>	124
Cytogenetics of embryonic stem cells	125
Engraftment, mobilization and expansion of stem cells	125
<i>Adipogenesis induced by adipose tissue-derived stem cells</i>	126
<i>Antisense approach for preservation and expansion of stem cells</i>	127
<i>Chemoattraction of neuronal stem cells through GABA receptor</i>	127
<i>Enhancement of HSC engraftment by calcium-sensing receptor</i>	128
<i>Enhancement of stem cell differentiation by Homspera</i>	128
<i>Ex vivo expansion of human HSCs in culture</i>	128
<i>Ex vivo expansion of MSCs</i>	129
<i>Expansion of HSCs in culture by inhibiting aldehyde dehydrogenase</i>	129
<i>Expansion of adult stem cells by activation of Oct4</i>	130
<i>Expansion of transduced HSCs in vivo</i>	130
<i>Mobilization of HSCs by growth factors</i>	130
<i>Mobilization of stem cells by cytokines/chemokines</i>	131
<i>Mobilization of adult human HSCs by use of inhibitors</i>	132
<i>Mobilization of stem cells by HYC750</i>	132
<i>Mobilization of stem cells by hyperbaric oxygen</i>	132
<i>Mobilization by adenoviral vectors expressing angiogenic factors</i>	133
<i>Selective mobilization of progenitor cells from bone marrow</i>	133
<i>Selective Amplification</i>	134
<i>Stem cell mobilization by acetylcholine receptor agonists</i>	134
<i>Use of parathyroid hormone to increase HSC mobilization</i>	134
<i>Expansion of stem cells in vivo by Notch receptor ligands</i>	134
Technologies for inducing differentiation of stem cells.....	135
<i>Use of lineage selection to induce differentiation of hESCs</i>	135
<i>Growth factor-induced differentiation of MAPCs</i>	135
<i>Neurotrophin-mediated survival and differentiation of hESCs</i>	135
<i>Generation of RBCs from hematopoietic stem cells</i>	136
<i>Generation of multiple types of WBCs from hESCs and iPSCs</i>	136
<i>Use of RNAi to expand the plasticity of autologous adult stem cells</i>	136
<i>Use of carbohydrate molecules to induce differentiation of stem cells</i>	137
<i>Mechanical strain to induce MSC differentiation</i>	137
Limitations of the currently available stem cell lines in the US	137
Contaminating material in stem cell culture and measures to eliminate it	138
Stem cell separation	139
Stem cell culture	140
Conversion of stem cells to functioning adipocytes	140
Mass production of ESCs	140
Promoting survival of dissociated hESCs	141
Analysis and characterization of stem cells	141
Havesting and identification of EPCs	141
Labeling of stem cells	142
<i>Quantum dots for labeling stem cells</i>	142
Imaging and tracking of stem cells in vivo	143
<i>Quantum dot imaging for ESCs</i>	143
<i>Perfluorocarbon nanoparticles to track therapeutic cells in vivo</i>	143
<i>Project for imaging in stem cell therapy research</i>	143
Applications of stem cells	144
Controlling the maintenance process of hematopoietic stem cells	144
<i>Self renewal and proliferation of HSCs</i>	144
<i>Aging and rejuvenation of HSCs</i>	145
Peripheral blood stem cell transplantation	145
<i>Complications of PBSC transplantation in children</i>	145
<i>Stem cell transplantation for radiation sickness</i>	146
Stem cells and human reproduction	146
<i>Expansion of spermatogonial stem cells</i>	146
<i>Conversion of ESCs into spermatogonial stem cells</i>	146
<i>Conversion of stem cells to oocytes</i>	147
<i>ESCs for treatment of infertility in women</i>	147
<i>Cloning human embryos from oocytes matured in the laboratory</i>	148
<i>In utero stem cell transplantation</i>	148
Innovations in delivery of stem cells	149
Immunological aspects of hESC transplantation	150

<i>Immunosuppression to prevent rejection of hESC transplants</i>	150
<i>Histocompatibility of hESCs</i>	150
<i>Strategies for promoting immune tolerance of hESCs</i>	151
Stem cells for organ vascularization	151
<i>Activation of EphB4 to enhance angiogenesis by EPCs</i>	152
Advantages and limitations of clinical applications of MSCs	152
Biofusion by genetically engineering stem cells	153
Stem cell gene therapy	153
<i>Combination of gene therapy with nuclear transfer</i>	153
<i>Gene delivery to stem cells by artificial chromosome expression</i>	153
<i>Genetic manipulation of ESCs</i>	154
<i>Genetic engineering of human stem cells for enhancing angiogenesis</i>	154
<i>HSCs for gene therapy</i>	154
<i>Helper-dependent adenoviral vectors for gene transfer in ESCs</i>	155
<i>Lentiviral vectors for in vivo gene transfer to stem cells</i>	155
<i>Linker based sperm-mediated gene transfer technology</i>	156
<i>Mesenchymal stem cells for gene therapy</i>	156
<i>Microporation for transfection of MSCs</i>	156
<i>Regulation of gene expression for SC-based gene therapy</i>	157
<i>Stem cells and in utero gene therapy</i>	157
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	157
<i>The future of hematopoietic stem cell gene therapy</i>	158
Stem cell pharmaceuticals	158
<i>Cardiomyocytes derived from hESCs</i>	158
<i>Engineered stem cells for drug delivery to the brain</i>	159
<i>ESCs as source of models for drug discovery</i>	159
<i>Hepatocytes derived from hESCs</i>	160
<i>Pharmaceutical manipulation of stem cells</i>	160
<i>Role of stem cells in therapeutic effects of drugs</i>	162
<i>Stem cells for drug discovery</i>	162
<i>Stem cell activation for regeneration by using glucocorticoids</i>	163
<i>Toxicology and drug safety studies using ESCs</i>	164
Future challenges for stem cell technologies	166
Study of the molecular mechanism of cell differentiation	166
MBD3-deficient ESC line	167
In vivo study of human hemopoietic stem cells	167
Stem cell biology and cancer	167
Research into plasticity of stem cells from adults	168
Stem cells and aging	168
Activation of bone marrow stem cells into therapeutic cells	169
Role of nitric oxide in stem cell mobilization and differentiation	169
Stem cell genes	170
<i>Gene expression in hESCs</i>	170
<i>The casanova gene in zebrafish</i>	171
<i>Nanog gene</i>	171
Stem cell proteomics	172
<i>hESC phosphoproteome</i>	173
<i>Proteomic studies of mesenchymal stem cells</i>	173
<i>Proteomic profiling of neural stem cells</i>	173
<i>Proteome Biology of Stem Cells Initiative</i>	174
Genomic alterations in cultured hESCs	174
Hybrid embryos/cybrids for stem cell research	174
Generation of patient-specific pluripotent stem cells	175
Markers for characterizing hESC lines	176
Switch of stem-cell function from activators to repressors	176
Stem cell research at academic centers	177
International Regulome Consortium	178
Companies involved in stem cell technologies	178
Concluding remarks about stem cells	183
Challenges and future prospects of stem cell research	183
4. Clinical Applications of Cell Therapy	185
Introduction	185
Cell therapy for hematological disorders	185
Transplantation of autologous hematopoietic stem cells	185
Hemophilias	185
<i>Ex vivo cell/gene therapy of hemophilia B</i>	185
<i>Cell/gene therapy of hemophilia A</i>	186
Hematopoietic stem cell therapy for thrombocytopenia	187
Stem cell transplant for sickle cell anemia	187
Treatment of chronic acquired anemias	188

<i>Implantation of genetically engineered HSCs to deliver rhEpo</i>	188
<i>Drugs acting on stem cells for treatment of anemia</i>	188
Stem cell therapy of hemoglobinopathies	189
Stem cells for treatment of immunoglobulin-light chain amyloidosis	189
Future prospects of cell therapy of hematological disorders	189
Cell therapy for immunological disorders	190
Role of dendritic cells in the immune system	190
Modifying immune responses of DCs by vaccination with lipiodol-siRNA mixtures	190
Stem cell therapy of chronic granulomatous disease	191
Stem cell therapy of X-linked severe combined immunodeficiency	191
Stem cell therapy of autoimmune disorders	192
<i>Treatment of Crohn's disease with stem cells</i>	192
<i>Treatment of rheumatoid arthritis with stem cells</i>	192
<i>Stem cell transplants for scleroderma</i>	193
Role of T-Cells in immunological disorders	193
<i>Autologous T-cells from adult stem cells</i>	194
Cell therapy for graft vs host disease	194
Cell therapy for viral infections	195
<i>T-cell therapy for CMV</i>	195
<i>T-cell therapy for HIV infection</i>	196
<i>T-cell immunity by Overlapping Peptide-pulsed Autologous Cells</i>	196
<i>Anti-HIV ribozyme delivered in hematopoietic progenitor cells</i>	197
<i>Dendritic-cell targeted DNA vaccine for HIV</i>	197
Cell therapy of lysosomal storage diseases	197
Niemann-Pick disease	198
Gaucher's disease	198
Fabry's disease	199
Cell therapy for diabetes mellitus	199
Limitations of current treatment	200
<i>Limitations of insulin therapy for diabetes mellitus</i>	200
<i>Limitations of pancreatic transplantation</i>	200
Islet cell transplantation	201
<i>Autologous pancreatic islet cell transplantation in chronic pancreatitis</i>	201
<i>Clinical trials of pancreatic islet cell transplants for diabetes</i>	201
<i>Drawbacks of islet cell therapy</i>	202
<i>Use of an antioxidant peptide to improve islet cell transplantation</i>	202
<i>Cdk-6 and cyclin D1 enhance human beta cell replication and function</i>	203
<i>A device for delivery of therapeutic cells in diabetes</i>	203
<i>Monitoring of islet cell transplants with MRI</i>	203
<i>Concluding remarks about allogeneic islet transplantation for diabetes</i>	204
Encapsulation of insulin producing cells	204
<i>Encapsulated porcine pancreatic islet cells for pancreas</i>	204
<i>Encapsulated insulinoma cells</i>	205
<i>Magnetocapsule enables imaging/tracking of islet cell transplants</i>	205
Islet precursor cells	206
Dedifferentiation of β cells to promote regeneration	206
Xenotransplantation of embryonic pancreatic tissue	207
Non-pancreatic tissues for generation of insulin-producing cells	207
Exploiting maternal microchimerism to treat diabetes in the child	207
Bio-artificial substitutes for pancreas	208
Role of stem cells in the treatment of diabetes	208
<i>Pancreatic stem cells</i>	208
<i>Embryonic stem cells for diabetes</i>	209
<i>Isolation of islet progenitor cells</i>	210
<i>Expansion of pancreatic progenitor cells in vitro</i>	210
<i>Human neural progenitor cells converted into insulin-producing cells</i>	210
<i>Insulin-producing cells derived from UCB stem cells</i>	211
<i>Stem cell injection into portal vein of diabetic patients</i>	211
<i>HSC transplantation to supplement immunosuppressant therapy</i>	211
Dendritic cell-based therapy for type 1 diabetes	212
Gene therapy in diabetes	212
<i>Viral vectors for gene therapy of diabetes</i>	212
<i>Genetically engineered dendritic cells</i>	213
<i>Genetically altered liver cells</i>	213
<i>Genetically modified stem cells</i>	214
Companies developing cell therapy for diabetes	214
Concluding remarks about cell and gene therapy of diabetes	215
Cell therapy of gastrointestinal disorders	216
Inflammatory bowel disease	216
Cell therapy for liver disorders	216
Types of cells and methods of delivery for hepatic disorders	217

Bioartificial liver	217
<i>Limitations of bioartificial liver</i>	218
Stem cells for hepatic disorders	218
<i>Deriving hepatocytes from commercially available hMSCs</i>	219
<i>Implantation of hepatic cells derived from hMSCs of adipose tissue</i>	220
<i>MSC derived molecules for reversing hepatic failure</i>	220
Cell-based gene therapy for liver disorders.....	220
<i>Transplantation of genetically modified fibroblasts</i>	221
<i>Transplantation of genetically modified hepatocytes</i>	221
<i>Intraperitoneal hepatocyte transplantation</i>	221
<i>Genetically modified hematopoietic stem cells</i>	221
Clinical applications	222
Future prospects of cell-based therapy of hepatic disorders	222
Cell therapy of renal disorders	223
Bioartificial kidney	223
Bone marrow stem cells for renal disease.....	223
Human stem cells to prevent end stage renal disease	224
<i>Role of stem cells in renal repair</i>	224
<i>Cell-based repair for vascular access failure in renal disease</i>	224
Mesangial cell therapy	225
Cell therapy for pulmonary disorders	225
Delivery of cell therapy for pulmonary disorders	225
<i>Intratracheal injection of cells for pulmonary hypoplasia</i>	225
Role of stem cells in pulmonary disorders.....	226
<i>Lung tissue regeneration from stem cells</i>	226
<i>Role of stem cells in construction of the Cyberlung</i>	226
<i>Respiratory epithelial cells derived from UCB stem cells</i>	227
<i>Respiratory epithelial cells derived from hESCs</i>	227
<i>Lung tissue engineering with adipose stromal cells</i>	227
<i>Cell-based tissue-engineering of airway</i>	228
Pulmonary disorders that are treatable by stem cells.....	228
<i>Acute lung injury and ARDS treated with MSCs</i>	229
Bronchopulmonary dysplasia treated with MSCs.....	230
<i>Cystic fibrosis treatment with genetically engineered MSCs</i>	230
<i>Pulmonary arterial hypertension treatment with EPCs</i>	230
Cell therapy for disorders of bones and joints	231
Repair of fractures and bone defects	231
<i>Adult stem cells for bone grafting</i>	232
<i>Cell therapy for osteonecrosis</i>	232
<i>ESCs for bone repair</i>	233
<i>Intrauterine use of MSCs for osteogenesis imperfecta</i>	233
<i>In vivo bone engineering as an alternative to cell transplantation</i>	233
<i>MSCs for repair of bone defects</i>	233
<i>MSCs for repair of bone fractures</i>	236
<i>Osteocel</i>	237
<i>Stem cells for repairing skull defects</i>	237
<i>Stem cell-based bone tissue engineering</i>	237
Osteoarthritis and other injuries to the joints.....	238
<i>Mosaicplasty</i>	239
<i>Autologous cultured chondrocytes</i>	239
<i>Autologous intervertebral disc chondrocyte transplantation</i>	240
<i>Cartilage repair by genetically modified fibroblasts expressing TGF-β</i>	241
<i>Generation of cartilage from stem cells</i>	241
Role of cell therapy in repair of knee cartilage injuries	243
<i>Role of cells in the repair of anterior cruciate ligament injury</i>	244
Autologous tenocyte implantation in rotator cuff injury repair	245
Platelet injection for tennis elbow	245
Cell therapy of rheumatoid arthritis	246
Cell therapy for diseases of the eye	246
Cell therapy for corneal repair	246
Stem cell therapy for limbal stem cell deficiency	248
Cell therapy for regeneration	248
Stem cells for regeneration	248
Stem cells for regenerating organs.....	249
Umbilical cord blood for regeneration	250
Promotion of regeneration by Wnt/beta-catenin signaling.....	250
Role of stem cells in regeneration of esophageal epithelium	251
Cell therapy for regeneration of muscle wasting	251
MSCs for regeneration of ovaries following radiotherapy damage	252
Wound healing: skin and soft tissue repair	252
Cells to form skin substitutes for healing ulcers	252

CellSpray for wound repair.....	253
Cell therapy for burns.....	254
Closure of incisions with laser guns and cells.....	254
Follicular stem cells for skin and wound repair.....	255
Genetically engineered cells for wound repair.....	255
Regeneration of skin by adipose-derived stem cells.....	255
Repair of aging skin by injecting autologous fibroblasts.....	256
Role of cells in tissue engineering and reconstructive surgery.....	256
Stem cells for tissue repair.....	256
Scaffolds for tissue engineering.....	257
Improving vascularization of engineered tissues.....	257
Enhancing vascularization by combining cell and gene therapy.....	257
Choosing cells for tissue engineering.....	258
ESCs vs adult SCs for tissue engineering.....	258
Use of adult MSCs for tissue engineering.....	259
Nanobiotechnology applied to cells for tissue engineering.....	259
Stem cells for tissue engineering of various organs.....	260
<i>Engineering of healthy living teeth from stem cells.....</i>	<i>260</i>
<i>Adipose tissue-derived stem cells for breast reconstruction.....</i>	<i>261</i>
<i>Improving tissue engineering of bone by MSCs.....</i>	<i>261</i>
<i>Intra-uterine repair of congenital defects using amniotic fluid MSCs.....</i>	<i>262</i>
Cell-based tissue engineering in genitourinary system.....	262
<i>Urinary incontinence.....</i>	<i>262</i>
<i>Tissue engineering of urinary bladder.....</i>	<i>263</i>
<i>Label retaining urothelial cells for bladder repair.....</i>	<i>264</i>
<i>Repair of the pelvic floor with stem cells from the uterus.....</i>	<i>264</i>
<i>Reconstruction of vagina from stem cells.....</i>	<i>264</i>
Facial skin regeneration by stem cells as an alternative to face transplant.....	265
Cell therapy for rejuvenation.....	265
Cell therapy for performance enhancement in sports.....	265
Application of stem cells in veterinary medicine.....	266
Use of stem cells to repair tendon injuries.....	266
Stem cells for spinal cord injury in dogs.....	266
5. Cell Therapy for Cardiovascular Disorders.....	268
Introduction to cardiovascular disorders.....	268
Limitations of current therapies for myocardial ischemic disease.....	268
Types of cell therapy for cardiovascular disorders.....	268
Cell-mediated immune modulation for chronic heart disease.....	269
Human cardiovascular progenitor cells.....	270
Inducing the proliferation of cardiomyocytes.....	270
Role of the SDF-1-CXCR4 axis in stem cell therapies for myocardial ischemia.....	271
Role of splenic myocytes in repair of the injured heart.....	271
Small molecules to enhance myocardial repair by stem cells.....	271
Cell therapy for atherosclerotic coronary artery disease.....	272
MyoCell™ (Bioheart).....	272
Cardiac stem cells.....	273
Cardiomyocytes derived from epicardium.....	273
Methods of delivery of cells to the heart.....	274
Cellular cardiomyoplasty.....	274
IGF-1 delivery by nanofibers to improve cell therapy for MI.....	274
Non-invasive delivery of cells to the heart by Morph@guide catheter.....	275
Cell therapy for cardiac revascularization.....	275
Transplantation of cardiac progenitor cells for revascularization of myocardium.....	275
Stem cells to prevent restenosis after coronary angioplasty.....	275
Role of cells in cardiac tissue repair.....	276
Transplantation of myoblasts for myocardial infarction.....	276
Patching myocardial infarction with fibroblast culture.....	277
Cardiac repair with myoendothelial cells from skeletal muscle.....	277
Myocardial tissue engineering.....	278
Role of stem cells in repair of the heart.....	279
Role of stem cells in cardiac regeneration following injury.....	279
Cardiomyocytes derived from adult skin cells.....	279
Cardiomyocytes derived from ESCs.....	279
Studies to identify subsets of progenitor cells suitable for cardiac repair.....	280
Technologies for preparation of stem cells for cardiovascular therapy.....	281
<i>Pravastatin for expansion of endogenous progenitor and stem cells.....</i>	<i>281</i>
<i>Cytokine preconditioning of human fetal liver CD133+ SCs.....</i>	<i>281</i>
<i>Expansion of adult cardiac stem cells for transplantation.....</i>	<i>282</i>
Role of ESCs in repair of the heart.....	282
<i>ESC transplantation for tumor-free repair of the heart.....</i>	<i>283</i>

Transplantation of stem cells for acute myocardial infarction	283
<i>Autologous bone marrow-derived stem cell therapeutics</i>	284
<i>Autologous bone marrow-derived mesenchymal precursor stem cells</i>	284
<i>Transplantation of cord blood stem cells</i>	284
<i>Transplantation of hESCs</i>	284
<i>Transplantation of HSCs</i>	285
<i>Transplantation of autologous angiogenic cell precursors</i>	286
<i>Transplantation of adipose-derived stem cells</i>	286
<i>Intracoronary infusion of bone marrow-derived cells for AMI</i>	287
<i>Intracoronary infusion of mobilized peripheral blood stem cells</i>	287
<i>Transplantation of endothelial cells</i>	288
<i>Transplantation of cardiomyocytes differentiated from hESCs</i>	288
Stem cell therapy for cardiac regeneration	288
<i>Regeneration of the chronic myocardial infarcts by HSC therapy</i>	289
<i>Human mesenchymal stem cells for cardiac regeneration</i>	289
<i>In vivo tracking of MSCs transplanted in the heart</i>	290
<i>MSCs for hibernating myocardium</i>	290
<i>Simultaneous transplantation of MSCs and skeletal myoblasts</i>	291
Transplantation of genetically modified cells	291
Transplantation of genetically modified MSCs	291
Transplantation of cells secreting vascular endothelial growth factor.....	291
Transplantation of genetically modified bone marrow stem cells.....	292
Cell transplantation for congestive heart failure	292
Myoblasts for treatment of congestive heart failure	292
Injection of adult stem cells for congestive heart failure.....	292
AngioCell gene therapy for congestive heart failure	293
Stem cell therapy for dilated cardiac myopathy.....	294
Role of cell therapy in cardiac arrhythmias	294
Atrioventricular conduction block	295
<i>Genetically engineered cells as biological pacemakers</i>	295
Ventricular tachycardia	296
Prevention of myoblast-induced arrhythmias by genetic engineering	296
ESCs for correction of congenital heart defects	296
Cardiac progenitors cells for treatment of heart disease	297
Autologous stem cells for chronic myocardial ischemia	297
Role of cells in cardiovascular tissue engineering	298
Construction of blood vessels with cells.....	298
Targeted delivery of endothelial progenitor cells labeled with nanoparticles	299
Fetal cardiomyocytes seeding in tissue-engineered cardiac grafts.....	299
UCB progenitor cells for engineering heart valves.....	299
Cell therapy for peripheral vascular disease	299
ALD-301	300
Cell/gene therapy for PVD	300
Colony stimulating factors for enhancing peripheral blood stem cells	300
Intramuscular autologous bone marrow cells.....	301
Vascular Repair Cell	301
Clinical trials of cell therapy in cardiovascular disease	301
Mechanism of the benefit of cell therapy for heart disease	304
A critical evaluation of cell therapy for heart disease	304
Publications of clinical trials of cell therapy for CVD	304
Current status of cell therapy for cardiovascular disease	305
Future directions for cell therapy of CVD	305
Prospects of adult stem cell therapy for repair of heart	305
Regeneration of cardiomyocytes without use of cardiac stem cells.....	306
6. Cell Therapy for Cancer	307
Introduction	307
Cell therapy technologies for cancer	307
Cellular immunotherapy for cancer	308
Treatments for cancer by ex vivo mobilization of immune cells	308
Granulocytes as anticancer agents	309
Neutrophil granulocytes in antibody-based immunotherapy of cancer	309
Cancer vaccines	310
Autologous tumor cell vaccines	310
<i>BIOVAXID</i>	310
<i>OncoVAX</i>	310
<i>Tumor cells treated with dinitrophenyl</i>	311
Vaccines that simultaneously target different cancer antigens.....	311
Gene modified cancer cells vaccines	311
<i>GVAX cancer vaccines</i>	311
<i>K562/GM-CSF</i>	312

Active immunotherapy based on antigen specific to the tumor	312
The use of dendritic cells for cancer vaccination	313
<i>Autologous dendritic cells loaded ex vivo with telomerase mRNA</i>	313
<i>Dendritic/tumor cell fusion</i>	313
<i>Genetically modified dendritic cells</i>	314
<i>In vivo manipulation of dendritic cells</i>	314
<i>Preclinical and clinical studies with DC vaccines</i>	314
<i>Vaccines based on dendritic cell-derived exosomes</i>	315
<i>Limitations of DC vaccines for cancer</i>	315
<i>Future developments to enhance clinical efficacy of DC vaccines</i>	315
Lymphocyte-based cancer therapies.....	317
<i>Adoptive cell therapy</i>	317
<i>Rescue of CD8+ T cells for use in tumor immunotherapy</i>	318
<i>Expansion of antigen-specific cytotoxic T lymphocytes</i>	318
<i>Genetically targeted T cells for treating B cell malignancies</i>	319
<i>Tumor infiltrating lymphocytes</i>	319
<i>Genetic engineering of tumor cells</i>	320
Hybrid cell vaccination	320
Stem cell-based anticancer therapies	321
Stem cell transplantation in cancer	321
<i>Peripheral blood stem cell transplantation</i>	321
<i>Stem cell transplantation for hematological malignancies</i>	323
<i>Complications of stem cell transplants in cancer</i>	324
<i>Long-term results of HSC transplantation</i>	325
<i>Prediction of T-cell reconstitution after HSC transplantation</i>	326
<i>HSC transplantation followed by GM-CSF-secreting cell vaccines</i>	326
Role of MSCs in cancer	327
Nonmyeloablative allogeneic hematopoietic stem cell transplantation	327
Umbilical cord blood transplant for leukemia.....	328
hESC-derived NK cells for treatment of cancer.....	328
ESC vaccine for prevention of lung cancer	329
Genetic modification of stem cells for cancer therapy.....	329
<i>Genetic modification of hematopoietic stem cells</i>	329
<i>Use of hematopoietic stem cells to deliver suicide genes to tumors</i>	329
<i>Delivery of anticancer agents by genetically engineered MSCs</i>	330
<i>Mesenchymal progenitor cells for delivery of oncolytic adenoviruses</i>	330
<i>Genetically modified NSCs for treatment of neuroblastoma</i>	331
Innovations in cell-based therapy of cancer	331
Use of immortalized cells	331
Cancer therapy based on natural killer cells.....	331
Mesothelin as a target for cancer immunotherapy	332
Nanomagnets for targeted cell-based cancer gene therapy.....	332
Implantation of genetically modified encapsulated cells for anticancer therapy.....	333
<i>Antiangiogenesis therapy by implantation of microencapsulated cells</i>	333
<i>Recombinant tumor cells secreting fusion protein</i>	333
<i>NovaCaps® for pancreatic cancer</i>	333
A device for filtering cancer and stem cells in the blood	333
Cancer stem cells.....	334
<i>Role of integrative nuclear signaling in stem cell development</i>	334
<i>Cancer stem cell markers</i>	335
<i>Breast cancer stem cells</i>	335
<i>Role of intestinal stem cells in intestinal polyposis</i>	336
<i>Role of endothelial progenitor cells in tumor angiogenesis</i>	336
<i>Role of cancer stem cells in metastases</i>	336
<i>Therapeutic implications of cancer stem cells</i>	336
<i>Targeting cancer stem cells in leukemia</i>	337
<i>Targeting stem cells in ovarian cancer</i>	338
<i>Targeting cancer stem cells to screen anticancer drugs</i>	338
Cell-based therapies for malignant brain tumors	338
<i>Role of cancer stem cells in resistance to radiotherapy</i>	339
<i>Targeting stem cells in brain tumors</i>	339
<i>Neural stem cells for drug/gene delivery to brain tumors</i>	339
<i>Mesenchymal stem cells for the treatment of gliomas</i>	341
<i>Bone morphogenetic protein for inhibition of glioblastoma multiforme</i>	341
<i>Dendritic cell therapy for brain tumors</i>	341
<i>Encapsulated cells for brain tumors</i>	342
Companies involved in cell-based cancer therapy	343
American Association for Cancer Research and ESCs	344
Future of cell-based immunotherapy for cancer.....	345

7. Cell Therapy for Neurological Disorders..... 346

Introduction.....	346
Regeneration of the nervous system by endogenous stem cells	346
Molecular mechanism of neurogenesis	346
Generation of neurons from astroglia.....	347
In vivo cell replacement therapy by locally induced neural progenitor cells	347
Types of cells used for treatment of neurological disorders	348
Activated T lymphocytes	348
Differentiation of placenta-derived multipotent cells into neurons.....	348
Mesenchymal stem cells induced to secrete neurotrophic factors	349
Neural stem cells	349
<i>Development of human CNS stem cells</i>	<i>349</i>
<i>Distinction between NSCs and intermediate neural progenitors</i>	<i>350</i>
<i>Embryonic stem cell-derived neurogenesis</i>	<i>350</i>
<i>Mechanism of migration of neural stem cells to sites of CNS injury</i>	<i>352</i>
<i>Monitoring of implanted NSCs labeled with nanoparticles</i>	<i>352</i>
<i>Neural progenitor cells.....</i>	<i>352</i>
<i>Neural stem cells as therapeutic delivery vehicles</i>	<i>354</i>
<i>Neural stem cells in the subventricular zone of the brain</i>	<i>355</i>
<i>Oligodendrocyte progenitor cells</i>	<i>355</i>
<i>Proteomics of neural stem cells.....</i>	<i>355</i>
<i>Regulation of neural stem cells in the brain</i>	<i>356</i>
<i>Sequencing the transcriptomes of neural stem cells.....</i>	<i>357</i>
<i>Study of neural differentiation of hESCs by NeuroStem Chip.....</i>	<i>357</i>
<i>Transformation of neural stem cells into other cell types</i>	<i>357</i>
<i>Use of epidermal neural crest stem cells for neurological disorders.....</i>	<i>357</i>
Olfactory epithelium stem cells for transplantation in the CNS	358
Development of CNS cells from extraneural stem cells.....	358
<i>Hair-follicle stem cells for neural repair</i>	<i>359</i>
<i>Stem cells from human umbilical cord blood for CNS disorders</i>	<i>359</i>
Immortalized cells for CNS disorders	360
Fetal tissue transplants	360
Choroid plexus cells.....	361
Laboratory mice with human brain cells	361
Expansion of adult human neural progenitors	361
Neurospheres	362
Dental pulp cells for neuroprotection	362
Ideal cells for transplantation into the nervous system	362
Cell therapy techniques for neurological applications	363
Carbon nanotubes to aid stem cell therapy of neurological disorders	363
Cells used for gene therapy of neurological disorders.....	363
<i>Fibroblasts</i>	<i>364</i>
<i>Stem cells</i>	<i>364</i>
<i>Neuronal cells.....</i>	<i>364</i>
<i>Immortalized neural progenitor cells.....</i>	<i>364</i>
<i>Astrocytes.....</i>	<i>365</i>
<i>Cerebral endothelial cells</i>	<i>365</i>
<i>Human retinal pigmented epithelial cells</i>	<i>366</i>
Enhancement of growth of stem cells in the brain by drugs	366
<i>C3-induced differentiation and migration of NPC for repair of the brain</i>	<i>367</i>
hESCs for CNS repair.....	367
Methods of delivery of cells to the CNS	368
Neuronal differentiation of stem cells.....	368
Stem cells preparations for CNS disorders	369
Tracking of stem cells in the CNS by nanoparticles and MRI	370
Use of neural stem cells to construct the blood brain barrier	370
<i>Encapsulated cells</i>	<i>370</i>
<i>CNS neotissue implant.....</i>	<i>371</i>
<i>Intrathecal delivery of stem cells.....</i>	<i>371</i>
<i>CNS delivery of cells by catheters</i>	<i>372</i>
<i>Intravascular administration</i>	<i>372</i>
Neurological disorders amenable to cell therapy	373
Neuroprotection by cell therapy	373
<i>Cells secreting neuroprotective substances.....</i>	<i>373</i>
<i>Stem cells for neuroprotection</i>	<i>373</i>
<i>Neuroprotection by intravenous administration of HSCs</i>	<i>374</i>
<i>Human UCB-derived stem cells for the aging brain</i>	<i>374</i>
<i>hESC transplantation to prevent cognitive impairment from radiation</i>	<i>374</i>
Neurodegenerative disorders	375
<i>Role of stem cells in neurodegenerative disorders</i>	<i>375</i>
<i>MSCs for therapy of neurodegenerative disorders.....</i>	<i>376</i>
<i>Role of NSCs in disorders associated with aging brain</i>	<i>377</i>

<i>NSCs for improving memory</i>	377
Parkinson's disease	377
<i>Origin and fate of dopamine neurons</i>	379
<i>Human dopaminergic neurons for PD</i>	379
<i>Graft survival-enhancing drugs</i>	380
<i>Xenografting porcine fetal neurons</i>	380
<i>Encapsulated cells for PD</i>	380
<i>Stem cells for PD</i>	381
<i>Stem cells for production of glial derived neurotrophic factor</i>	383
<i>Potential of regeneration of endogenous stem cells in PD</i>	383
<i>Human retinal pigment epithelium cells for PD</i>	384
<i>Coaxing hESCs to produce dopamine</i>	384
<i>Tumorigenic potential of transplanted dopaminergic hESCs</i>	385
<i>Transplantation of embryonic medial ganglionic eminence cells</i>	385
<i>Delivery of cells for PD</i>	386
<i>MSCs for multiple system atrophy</i>	386
Cell therapy for Huntington's disease.....	386
<i>Fetal striatal cell transplantation</i>	386
<i>Transplantation of encapsulated porcine choroids plexus cells</i>	387
Cell therapy for Alzheimer's disease	387
<i>Neural stem cell implantation for Alzheimer's disease</i>	387
<i>Implantation of genetically engineered cells producing NGF</i>	388
Cell therapy for amyotrophic lateral sclerosis.....	388
<i>Stem cell techniques for study of ALS</i>	389
<i>Use of stem cells for ALS</i>	389
<i>Transplantation of glial restricted precursors in ALS</i>	390
<i>Stem cell-based drug discovery for ALS</i>	391
Cell therapy for lysosomal storage disorders.....	391
<i>Cell therapy for Batten disease</i>	391
<i>Cell/gene therapy for Farber's disease</i>	392
<i>Genetically modified HSCs for metachromatic leukodystrophy</i>	392
Cell therapy for demyelinating disorders	393
<i>Autologous bone marrow stem cell therapy for MS</i>	393
<i>ESCs for remyelination</i>	393
<i>Fusokine method of personalized cell therapy of multiple sclerosis</i>	394
<i>Hematopoietic stem cell transplantation for multiple sclerosis</i>	394
<i>Mechanism of repair of demyelination after NSC transplantation</i>	395
<i>Stem cells for chronic inflammatory demyelinating polyneuropathy</i>	396
<i>X-linked adrenoleukodystrophy</i>	396
Cell therapy of stroke	396
<i>Adult stem cell therapy in stroke</i>	397
<i>Implantation of genetically programmed ESCs</i>	397
<i>Intravenous infusion of marrow stromal cells</i>	398
<i>Intravenous infusion of UCB stem cells</i>	398
<i>Intracerebral administration of human adipose tissue stromal cells</i>	399
<i>Intracerebral administration of multipotent adult progenitor cells</i>	399
<i>Neural stem cell therapy for stroke</i>	399
<i>Transplantation of encapsulated porcine choroids plexus</i>	400
<i>Transplantation of fetal porcine cells</i>	401
<i>Future of cell therapy for stroke</i>	401
Cell therapy of traumatic brain injury	402
<i>Cell/gene therapy for TBI</i>	402
<i>Clinical trials of autologous HSC therapy for TBI</i>	402
<i>Limitations of stem cell therapy for acute TBI</i>	403
<i>Improving the microenvironments of transplanted cells in TBI</i>	403
Cell therapy for spinal cord injury	403
<i>Fetal neural grafts for SCI</i>	404
<i>Olfactory-ensheathing cells for SCI</i>	404
<i>Oligodendrocyte precursor cells for treatment of SCI</i>	405
<i>Schwann cell transplants for SCI</i>	405
<i>Transplantation of glial cells for SCI</i>	405
Stem cells for SCI	406
<i>Bone marrow stem cells for SCI</i>	406
<i>Embryonic stem cells for SCI</i>	406
<i>Transplantation of MSCs for SCI</i>	407
<i>Transplantation of NSCs for SCI</i>	407
<i>Transdifferentiation of BM stem cells into cholinergic neurons for SCI</i>	408
Spinal stem cells for treatment of ischemic injury of spinal cord.....	408
Combined approaches for regeneration in SCI	409
<i>Combined cell/gene therapy for SCI</i>	409
Delivery of cells in SCI.....	409

<i>Intrathecal injection of cells labeled with magnetic nanoparticles</i>	410
<i>Intravenous injection of stem cells for spinal cord repair</i>	410
Clinical applications of stem cells for SCI.....	410
<i>Autologous bone marrow cell transplantation for SCI</i>	410
<i>Cell therapy of syringomyelia</i>	411
Cell therapy for neurogenetic disorders.....	411
<i>Hurler's syndrome treated with stem cells</i>	411
<i>Krabbe's disease treated with UCB stem cells</i>	412
<i>Krabbe's disease treated with combination of cell and gene therapy</i>	412
<i>Mitochondrial encephalomyopathies treated with stem cells</i>	412
<i>Sanfilippo syndrome type B treated with UCB stem cells</i>	413
Cell therapy of epilepsy	413
<i>Cell therapy of posttraumatic epilepsy</i>	413
<i>Cell therapy for temporal lobe epilepsy</i>	414
<i>Cell therapy for pharmaco-resistant epilepsies</i>	414
Cell therapy for developmental neurological disorders.....	415
Cell therapy for cerebral palsy	415
Cell therapy for muscular dystrophy	415
<i>Combination of cell and pharmacotherapy for DMD</i>	416
<i>Myoblast transplant for Duchenne muscular dystrophy</i>	416
<i>Myoblast-based gene transfer</i>	417
<i>Myoblasts lacking the MyoD gene</i>	417
<i>Myoblast injection for treatment of other muscular dystrophies</i>	417
<i>Role of satellite cells in the treatment of DMD</i>	418
<i>Stem cells for DMD</i>	418
Cell therapy for Autism	420
Management of chronic intractable pain by cell therapy	420
<i>Implantation of chromaffin cells</i>	420
<i>Role of stem cells in management of pain</i>	421
<i>Implantation of astrocytes secreting enkephalin</i>	421
<i>Cells for delivery of antinociceptive molecules</i>	422
<i>Implantation of genetically engineered cells</i>	422
<i>Cell therapy for low back pain</i>	422
Cell therapy for retinal degenerative disorders.....	423
<i>Genetically engineered retinal pigmented epithelial cell lines</i>	424
<i>Delivery of CNTF by encapsulated cell intraocular implants</i>	424
<i>Stem cell transplantation in the retina</i>	424
<i>Isolation of RPE cells from hESCs using transcriptomics</i>	425
<i>ESCs for retinal degenerative disorders</i>	425
<i>Neuroprotective effect of neural progenitor cell transplantation</i>	425
<i>Human retinal stem cells</i>	426
<i>Combining cell and gene therapies for retinal disorders</i>	426
Stem cell therapy for hearing loss.....	426
Cell therapy for peripheral nerve lesions.....	427
<i>Cell transplants for peripheral nerve injuries</i>	427
<i>Treatment of diabetic neuropathy with endothelial progenitor cells</i>	427
Clinical trials of cell therapy in neurological disorders	428
Future prospects for cell therapy of CNS disorders	429
8. Ethical, Regulatory, and Safety Aspects of Cell Therapy	431
Introduction	431
Safety issues of cell therapy	431
Immune-mediated reactions to transplanted stem cells	431
Human virus infections associated with stem cell transplantation	432
<i>Herpes simplex virus type 1</i>	432
<i>Cytomegalovirus</i>	432
Opportunistic infections among hematopoietic stem cell transplant recipients	432
Carcinogenic potential of stem cells and its prevention	433
FDA safety regulations for cell and tissue products	433
FDA Guidance on license applications for umbilical cord blood products.....	433
Political and ethical aspects of hESC research in the US	434
Ethical issues concerning fetal tissues.....	434
<i>Morality and hESC research</i>	435
Opponents of hESC research in the US	435
<i>Use of hESCs in NIH-supported research</i>	436
<i>Public opinion in the US about hESC research</i>	438
<i>Human stem cell cloning in the US</i>	439
<i>Stem cell guidelines of various US institutions</i>	439
Ethics of transplanting human NSCs into the brains of nonhuman primates	441
Stem cell lines available worldwide	441
Stem cell policies around the world	442

Countries with no defined policies on hESC research.....	443
Australia	443
Canada	444
China	444
Denmark.....	445
France	445
Germany.....	446
India	447
Ireland	448
Israel	448
Italy	449
Japan	449
The Netherlands	450
Saudi Arabia.....	450
Singapore	450
South Africa	451
South Korea	451
Spain	451
Sweden	452
Switzerland	452
United Kingdom	453
<i>ESC bank</i>	453
European Union	454
<i>EU guidelines for stem cell research</i>	454
<i>EMBO's recommendations for stem cell research</i>	456
United Nations, cloning and nuclear transfer	457
The Embryo Project for information on ESC research	457
Concluding remarks about ethics of ESC research	457
Ethical issues concerning umbilical cord blood	458
Cell therapy tourism	458
Regulatory issues	459
Regulation of cord blood banks in the US	459
Regulatory issues for biotechnology-derived drugs	459
Regulation of cell selection devices for production of PBSCs at point of care	459
FDA rules for human cells and tissues.....	460
FDA regulation of fetal cellular or tissue products	461
FDA and clinical trials using hESCs	461
Cell and gene therapy INDs placed on hold by the FDA	462
Regulatory issues for genetically engineered cell transplants	463
FDA guidelines for human tissue transplantation	463
Xenotransplantation	463
<i>Clinical Protocol Review and Oversight</i>	463
<i>Informed consent and patient education</i>	464
<i>Xenotransplantation product sources</i>	464
<i>FDA guidelines for xenografts</i>	465
Regulations relevant to cell therapy in the European Union	466
<i>Regulations about use of stem cells</i>	467
<i>EMA regulation of cell/gene therapy</i>	467
<i>Guidelines for cell therapy in the UK</i>	468
NIH and stem cells.....	468
hESC lines approved under the new NIH guidelines	469
Clinical trials in cell therapy.....	469
Stem cell patents	470
Stem cell patents in the United States	470
<i>Current status of Thomson patents at WARF</i>	470
Stem cell patents in the European Union	471
9. References.....	473

Tables

Table 1-1: Landmarks in the history of cell therapy	25
Table 1-2: Examples of cells involved in various diseases.....	30
Table 2-1: Types of human cells used in cell therapy	33
Table 2-2: A selection of companies providing cell culture media	37
Table 2-3: A sampling of companies supplying cell sorters	40
Table 2-4: Companies involved in cell-based drug discovery	46
Table 2-5: Methods of delivery of cells for therapeutic purposes	48
Table 2-6: Therapeutic applications of encapsulated cells.....	52
Table 2-7: Companies working on encapsulated cell technology.....	55
Table 2-8: Molecular imaging methods for tracking cells in vivo	60
Table 3-1: Companies involved in cord blood banking as a source of stem cells	96
Table 3-2: Sources of adult human stem cells	103
Table 3-3: Enhancing engraftment, mobilization and expansion of stem cells	126
Table 3-4: Applications of stem cells	144
Table 3-5: Advantages and limitations of methods for optimizing MSCs	152
Table 3-6: Growth factors with positive effects on stem cells and applications	161
Table 3-7: Examples of drugs that induce granulocytopenia at stem cell level	165
Table 3-8: Academic institutes involved in stem cell research	177
Table 3-9: Companies involved in stem cell technologies	178
Table 4-1: Therapeutic applications of regulatory T cells (T-regs)	194
Table 4-2: Various tissue/cell therapy approaches to the treatment of type 1 diabetes	199
Table 4-3: Companies involved in cell therapy for insulin-dependent diabetes	214
Table 4-4: Major pulmonary disorders potentially treatable by stem cell manipulation	228
Table 4-5: Cell-based repair of knee cartilage damage	243
Table 5-1: Classification of various types of cell therapy for cardiovascular disorders	268
Table 5-2: Clinical trials of cell therapy in cardiovascular disease	301
Table 6-1: Cell therapy technologies used for cancer	307
Table 6-2: Companies involved in developing cell-based therapies for cancer	343
Table 7-1: Experimental use of immortalized cells for CNS disorders	360
Table 7-2: Methods for delivering cell therapies in CNS disorders.....	368
Table 7-3: Neurological disorders amenable to cell therapy.....	373
Table 7-4: Types of cell used for investigative treatment of Parkinson's disease.....	378
Table 7-5: Status of cell therapies for Parkinson's disease.....	378
Table 7-6: Clinical trials with cell-based therapies in neurological disorders	428
Table 8-1: Possible adverse reactions and safety issues of cell therapy	431
Table 8-2: Listed numbers of stem cell lines around the world as of end of 2008	442
Table 8-3: Stem cell policies around the world.....	442

Figures

Figure 1-1: Interrelationships of cell therapy to other technologies	27
Figure 1-2: Interrelationships of gene, cell and protein therapies	29
Figure 3-1: A simplified biological scheme of embryonic stem Cells	67
Figure 3-2: Steps of iPS cell production	100
Figure 3-3: Flow chart of development of stem cells with potential bottlenecks.....	184
Figure 5-1: hESC-derived cardiomyocytes from laboratory to bedside	280
Figure 6-1: A scheme of generation and administration of tumor antigen-pulsed dendritic cells	316
Figure 6-2: Stem cell transplantation techniques	322
Figure 7-1: Stem cells that can give rise to neurons.....	354
Figure 7-2: Approaches to stem cell therapy in stroke	397